Humanin vs Teriparatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Humanin
Humanin is a mitochondrial-derived peptide with potent cytoprotective effects. Discovered in 2001, it has shown promise in protecting against age-related diseases including Alzheimer's, cardiovascular disease, and diabetes.
Full details →Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →Side-by-Side Comparison
| Aspect | Humanin | Teriparatide |
|---|---|---|
| Mechanism | Binds to IGFBP-3 and BAX, inhibiting apoptosis. Activates STAT3 signaling and enhances cellular survival under stress. Protects mitochondrial function and reduces oxidative stress. | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. |
| Typical Dosage | Research protocols vary widely. Studies have used doses from micrograms to milligrams depending on the analog and route. HNG (S14G-Humanin) is a more potent analog. | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. |
| Administration | Subcutaneous or intraperitoneal injection in research. Various analogs exist with different potencies and stabilities. | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. |
| Side Effects | Limited human data. Generally well-tolerated in animal studies. May affect glucose metabolism. | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. |
| Best For |